The changing role of the gastroenterologist in the management of advanced gastric cancer.
Abstract
Gastric cancer remains a leading cause of cancer-related mortality worldwide despite advances in prevention and systemic therapy. Recent integration of precision oncology has transformed its management, shifting treatment selection toward biomarker-driven strategies. In this context, the gastroenterologist-endoscopist plays a pivotal role as the first gatekeeper in the diagnostic and therapeutic pathway. Adequate endoscopic sampling is essential to obtain representative tumor tissue and enable reliable molecular profiling. Current clinical decision-making relies on validated predictive biomarkers, including HER2, PD-L1, microsatellite instability/mismatch repair deficiency, and Claudin-18.2, while additional targets such as FGFR2b and EBV status are emerging. These biomarkers guide the use of targeted agents and immune checkpoint inhibitors, which have significantly improved outcomes in advanced disease. However, spatial and temporal tumor heterogeneity, limited tissue availability, and variability in testing methods remain major challenges for optimal patient selection and treatment sequencing. Multidisciplinary collaboration between gastroenterologists, pathologists and oncologists is therefore essential to ensure standardized biopsy procedures, accurate biomarker assessment, and appropriate therapeutic allocation. This review highlights the evolving role of the endoscopist beyond diagnosis, emphasizing the importance of high-quality sampling, repeat biopsy strategies and integration of novel technologies, such as liquid biopsy and digital pathology. A structured biomarker-driven workflow is proposed to optimize personalized treatment strategies across the gastric cancer continuum of care.